Now showing items 1-20 of 3786

    • Gene-environment dependence creates spurious gene-environment interaction. 

      Dudbridge, F; Fletcher, O (2014-09)
      Gene-environment interactions have the potential to shed light on biological processes leading to disease and to improve the accuracy of epidemiological risk models. However, relatively few such interactions have yet been ...
    • Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. 

      Gulati, S; Martinez, P; Joshi, T; Birkbak, NJ; Santos, CR; Rowan, AJ; Pickering, L; Gore, M; Larkin, J; Szallasi, Z; Bates, PA; Swanton, C; Gerlinger, M (2014-11)
      BACKGROUND:Candidate biomarkers have been identified for clear cell renal cell carcinoma (ccRCC) patients, but most have not been validated. OBJECTIVE:To validate published ccRCC prognostic biomarkers in an independent ...
    • Candidate gene-environment interactions in breast cancer. 

      Fletcher, O; Dudbridge, F (2014-10-17)
      Gene-environment interactions have the potential to shed light on biological processes leading to disease, identify individuals for whom risk factors are most relevant, and improve the accuracy of epidemiological risk ...
    • Sex specific retinoic acid signaling is required for the initiation of urogenital sinus bud development. 

      Bryant, SL; Francis, JC; Lokody, IB; Wang, H; Risbridger, GP; Loveland, KL; Swain, A (2014-11)
      The mammalian urogenital sinus (UGS) develops in a sex specific manner, giving rise to the prostate in the male and the sinus vagina in the embryonic female. Androgens, produced by the embryonic testis, have been shown to ...
    • Targeting molecular addictions in cancer. 

      Vivanco, I (2014-11)
      Cancer cells depend on a finite number of critical signals for their survival. Oncogene addiction, that is, the acquired dependence of a cancer cell on the activity of a single oncogenic gene product, has been the basis ...
    • Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. 

      Blazeby, JM; Hall, E; Aaronson, NK; Lloyd, L; Waters, R; Kelly, JD; Fayers, P (2014-12)
      Well-developed and well-tested patient-reported outcome measures for non-muscle-invasive bladder cancer (NMIBC) are required.To test and adapt the scale structure and explore the psychometric properties of the European ...
    • Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. 

      Lorente, D; Omlin, A; Ferraldeschi, R; Pezaro, C; Perez, R; Mateo, J; Altavilla, A; Zafeirou, Z; Tunariu, N; Parker, C; Dearnaley, D; Gillessen, S; de Bono, J; Attard, G (2014-12)
      BACKGROUND:Abiraterone is a CYP17A1 inhibitor that improves survival in castration-resistant prostate cancer (CRPC). Abiraterone is licensed in combination with prednisone 5 mg twice daily to prevent a syndrome of secondary ...
    • A kinase-independent function of AKT promotes cancer cell survival. 

      Vivanco, I; Chen, ZC; Tanos, B; Oldrini, B; Hsieh, W-Y; Yannuzzi, N; Campos, C; Mellinghoff, IK (2014-12-31)
      The serine-threonine kinase AKT regulates proliferation and survival by phosphorylating a network of protein substrates. In this study, we describe a kinase-independent function of AKT. In cancer cells harboring gain-of-function ...
    • PET/MRI in Oncological Imaging: State of the Art. 

      Bashir, U; Mallia, A; Stirling, J; Joemon, J; MacKewn, J; Charles-Edwards, G; Goh, V; Cook, GJ (2015-01)
      Positron emission tomography (PET) combined with magnetic resonance imaging (MRI) is a hybrid technology which has recently gained interest as a potential cancer imaging tool. Compared with CT, MRI is advantageous due to ...
    • Visualizing cellular imaging data using PhenoPlot. 

      Sailem, HZ; Sero, JE; Bakal, C (2015-01-08)
      Visualization is essential for data interpretation, hypothesis formulation and communication of results. However, there is a paucity of visualization methods for image-derived data sets generated by high-content analysis ...
    • Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. 

      Litchfield, K; Summersgill, B; Yost, S; Sultana, R; Labreche, K; Dudakia, D; Renwick, A; Seal, S; Al-Saadi, R; Broderick, P; Turner, NC; Houlston, RS; Huddart, R; Shipley, J; Turnbull, C (2015-01-22)
      Testicular germ cell tumours (TGCTs) are the most common cancer in young men. Here we perform whole-exome sequencing (WES) of 42 TGCTs to comprehensively study the cancer's mutational profile. The mutation rate is uniformly ...
    • Molecular similarity considerations in the licensing of orphan drugs. 

      Franco, P; Porta, N; Holliday, JD; Willett, P (2017-02)
      The large costs associated with modern drug discovery mean that governments and regulatory bodies need to provide economic incentives to promote the development of orphan drugs (i.e., medicinal products that are designed ...
    • Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial. 

      Cox, E; Saramago, P; Kelly, J; Porta, N; Hall, E; Tan, WS; Sculpher, M; Soares, M (2019-12-14)
      BACKGROUND:Limited evidence exists regarding the cost and health-related quality of life (HRQoL) effects of non-muscle-invasive bladder cancer (NMIBC) recurrence and progression to muscle-invasive bladder cancer (MIBC). ...
    • FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. 

      Boellaard, R; Delgado-Bolton, R; Oyen, WJG; Giammarile, F; Tatsch, K; Eschner, W; Verzijlbergen, FJ; Barrington, SF; Pike, LC; Weber, WA; Stroobants, S; Delbeke, D; Donohoe, KJ; Holbrook, S; Graham, MM; Testanera, G; Hoekstra, OS; Zijlstra, J; Visser, E; Hoekstra, CJ; Pruim, J; Willemsen, A; Arends, B; Kotzerke, J; Bockisch, A; Beyer, T; Chiti, A; Krause, BJ; European Association of Nuclear Medicine (EANM) (2015-02)
      The purpose of these guidelines is to assist physicians in recommending, performing, interpreting and reporting the results of FDG PET/CT for oncological imaging of adult patients. PET is a quantitative imaging technique ...
    • Issues involved in the quantitative 3D imaging of proton doses using optical CT and chemical dosimeters. 

      Doran, S; Gorjiara, T; Kacperek, A; Adamovics, J; Kuncic, Z; Baldock, C (2015-01-02)
      Dosimetry of proton beams using 3D imaging of chemical dosimeters is complicated by a variation with proton linear energy transfer (LET) of the dose-response (the so-called 'quenching effect'). Simple theoretical arguments ...
    • Genetic and functional diversity of propagating cells in glioblastoma. 

      Piccirillo, SGM; Colman, S; Potter, NE; van Delft, FW; Lillis, S; Carnicer, M-J; Kearney, L; Watts, C; Greaves, M (2015-01)
      Glioblastoma (GBM) is a lethal malignancy whose clinical intransigence has been linked to extensive intraclonal genetic and phenotypic diversity and the common emergence of therapeutic resistance. This interpretation ...
    • Expression of the fetal hematopoiesis regulator FEV indicates leukemias of prenatal origin. 

      Liu, T-H; Tang, Y-J; Huang, Y; Wang, L; Guo, X-L; Mi, J-Q; Liu, L-G; Zhu, H; Zhang, Y; Chen, L; Liu, X; Zhang, L-H; Ye, Q-J; Li, B-S; Tang, J-Y; Ford, A; Enver, T; Liu, F; Chen, G-Q; Hong, D-L (2017-05)
      The origin of cancers is associated with etiology as well as therapeutics. Several studies reveal that malignancies in children can originate in utero. However, a diagnostic approach to distinguish between cancers initiated ...
    • Origins of STIL-TAL1 fusion genes in children who later developed paediatric T-cell acute lymphoblastic leukaemia: An investigation of neonatal blood spots. 

      Gustafsson, BM; Mattsson, K; Bogdanovic, G; Leijonhufvud, G; Honkaniemi, E; Ramme, K; Ford, AM (2018-11)
      SCL/TAL1 interrupting locus (STIL)-T-cell acute leukaemia (TAL1) fusion genes are present in approximately 11-27% of children with paediatric T-cell acute lymphoblastic leukaemia (T-ALL), but the developmental timing of ...
    • Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. 

      Girotti, MR; Lopes, F; Preece, N; Niculescu-Duvaz, D; Zambon, A; Davies, L; Whittaker, S; Saturno, G; Viros, A; Pedersen, M; Suijkerbuijk, BMJM; Menard, D; McLeary, R; Johnson, L; Fish, L; Ejiama, S; Sanchez-Laorden, B; Hohloch, J; Carragher, N; Macleod, K; Ashton, G; Marusiak, AA; Fusi, A; Brognard, J; Frame, M; Lorigan, P; Marais, R; Springer, C (2015-01)
      BRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse with acquired resistance, and others present intrinsic resistance to these drugs. Resistance is often mediated by pathway ...
    • Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. 

      Hill, RM; Kuijper, S; Lindsey, JC; Petrie, K; Schwalbe, EC; Barker, K; Boult, JKR; Williamson, D; Ahmad, Z; Hallsworth, A; Ryan, SL; Poon, E; Robinson, SP; Ruddle, R; Raynaud, FI; Howell, L; Kwok, C; Joshi, A; Nicholson, SL; Crosier, S; Ellison, DW; Wharton, SB; Robson, K; Michalski, A; Hargrave, D; Jacques, TS; Pizer, B; Bailey, S; Swartling, FJ; Weiss, WA; Chesler, L; Clifford, SC (2015-01)
      We undertook a comprehensive clinical and biological investigation of serial medulloblastoma biopsies obtained at diagnosis and relapse. Combined MYC family amplifications and P53 pathway defects commonly emerged at relapse, ...